Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 144 No. 0910 (2014)

Forty years of haematopoietic stem cell transplantation: a review of the Basel experience

  • Alix Catherine O'Meara
  • Andreas Holbro
  • Sara Meyer
  • Maria Martinez
  • Michael Medinger
  • Andreas Buser
  • Joerg Halter
  • Dominik Heim
  • Sabine Gerull
  • Christoph Bucher
  • Alicia Rovo
  • Thomas Kuehne
  • André Tichelli
  • Alois Gratwohl
  • Martin Stern
  • Jakob Passweg
Cite this as:
Swiss Med Wkly. 2014;144:w13928


The purpose of this study was to examine changes in haematopoietic stem cell transplant (HSCT) characteristics and outcome in our combined paediatric and adult programme over the past four decades, since its implementation in 1973. The total number of transplant procedures rose from 109 in the first decade (1973–82) to 939 in the last decade (2003–12). Transplant characteristics changed significantly over time: patient age increased, peripheral blood largely replaced bone marrow as stem cell source, unrelated donors became an alternative to matched siblings, and patients are increasingly transplanted in more advanced disease stages.

Advances such as improved supportive care and histocompatibility typing resulted in a steady decrease of transplant-related mortality after allogeneic HSCT (43% in the first decade, 22% in the last decade). Despite this, unadjusted survival rates were stable in the last three decades for allogeneic HSCT (approximately 50% 5–year survival) and in the last two decades for autologous HSCT (approximately 60% 5–year survival). After adjustment for covariates such as donor type, age and stage, the relative risk of treatment failure continuously dropped (for allogeneic HSCT: first decade 1.0, second decade 0.58, third decade 0.51, last decade 0.41). Collectively, these data suggest that improvements in peri- and post-transplant care have allowed considerable extension of transplant indications without having a negative impact on outcome.


  1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26.
  2. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, et al. The EBMT activity survey: 1990–2010. Bone Marrow Transplant. 2012;47(7):906–23.
  3. Thomas ED and Blume KG. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 1999;5(6):341–6.
  4. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347(8998):353–7.
  5. Ballen KK, Koreth J, Chen YB, Dey BR, and Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012;119(9):1972–80.
  6. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576–83.
  7. Pavletic SZ and Fowler DH. Are we making progress in GVHD prophylaxis and treatment? Am Soc Hematol Educ Program. 2012:251–64.
  8. Marr KA. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Am Soc Hematol Educ Program. 2012:265–70.
  9. Halter J, Passweg JR, and Hausermann P. Future trends in hematopoietic stem cell transplantation. Curr Probl Dermatol. 2012;43:165–70.
  10. Gyurkocza B, Rezvani A, and Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol. 2010;3(3):285–99.
  11. WBMT, 1 millionth blood stem cell transplant marks major medical milestone. 2013.
  12. Buckner CD. Remembering Bruno Speck. Acta Haematologica. 2000;103:5–6.
  13. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47(6):749–56.
  14. Jain N. and van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011;25(5):1025–48.
  15. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349(1):17–26.
  16. Blaise D and Castagna L. Do different conditioning regimens really make a difference? Am Soc Hematol Educ Program. 2012;237–45.
  17. Passweg JR, Baldomero H, Stern M, Bargetzi M, Ghielmini M, Leibundgut K, et al. Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect. Swiss Med Wkly. 2010;140(23–24):326–34.
  18. Loberiza FR, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood. 2005;105(7):2979–87.
  19. O'Meara A, Halter J, Heim D, Gerull S, Bucher C, Passweg JR, et al. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. Biol Blood Marrow Transplant. 2013;19(1):82–6.
  20. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.
  21. Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Sadelin M, et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010;16(8):1037–69.

Most read articles by the same author(s)

1 2 > >>